A Recombinant Vaccinia Virus Expressing Herpes Simplex Virus Type 1 Glycoprotein B Induces Cytotoxic T Lymphocytes in Mice

SUMMARY
Spleen cells from BALB/c (H-2 o) mice vaccinated with vgBll, a recombinant vaccinia virus which expresses glycoprotein B (gB) of herpes simplex virus type 1 (HSV-1), lysed EMT6 (H-2 a) target cells infected with vgB 11 or with HSV-1 but did not lyse uninfected EMT6 cells or infected L-929 (H-2 k) target cells. Unlabelled target cell competition of lysis showed that only syngeneic cells infected with vgB11 or HSV-1 inhibited lysis of radiolabelled HSV-l-infected targets. These results demonstrate that vgB11 induces H-2-restricted anti-HSV-1 cytotoxic T lymphocytes and that gB is the target antigen.
Herpes simplex virus type 1 (HSV-1) produces primary and recurrent epithelial eruptions in man. Experimental studies in mice have shown that T cell immunity, and particularly cytotoxic T cells (CTL), are important in the rapid clearance of virus at the inoculation site (Nash et al., 1985) . Information is incomplete as to the specific HSV-1 antigens that serve as CTL targets. Experimental evidence indicates that HSV-I glycoprotein C (gC) is a major target antigen (Glorioso et al., 1985; Rosenthal et al., 1987) , whereas results have been negative for gD Blacklaws et al., 1987; Rosenthal et al., 1987) and conflicting for gB (Blacklaws et al., 1987; Rosenthal et al., 1987) . The evidence from most of these studies comes either from immunization of mice with HSV-1 mutants deficient in particular glycoproteins (Carter et al., 1981; Glorioso et al., 1985) or with transformed cell lines that express a specific HSV-1 glycoprotein on the cell surface (Blacklaws et al., 1987; Rosenthal et al., 1987) . An alternative approach to determine the role of individual viral proteins as CTL target antigens has been to immunize mice with recombinant vaccinia viruses that express a single HSV-1 glycoprotein. This approach has proved successful in other viral systems (Bennink et al., 1984; Wiktor et al., 1984) and has been used with HSV-1 gD . We have recently constructed a vaccinia virus recombinant (termed vgB 11) expressing HSV-1 gB (Cantin et al., 1987) . Glycoprotein B is expressed on the surface of vgBll-infected cells and is electrophoretically and antigenically indistinguishable from gB produced in HSV-l-infected cells. Here we report that vaccination with vgB I 1 induces anti-HSV CTL in BALB/c mice and that vgB11-infected ceils can serve as CTL targets in this system.
Male 6 to 8 weeks old BALB/c mice (H-2 a) were vaccinated with 107 p.f.u, of vgBll by tail scarification (Cremer et al., 1985) . Six days after vaccination, a secondary immunization was performed. Single-cell suspensions were prepared from the spleens of vaccinated mice, and infectious HSV-1 (strain F) or vgB11 was added at 5 to 10 p.f.u, per cultured spleen cell. . Each point represents a mean of triplicates where the standard error of the mean was ~< 5 %. The percentage specific release was determined by the quotient x 100 of test release minus spontaneous release divided by maximum release minus spontaneous release. days of culture in vitro for restimulation of memory CTL, spleen cells were harvested and used as effector cells in a standard 51Cr release, cell-mediated lympholysis assay (Lawman et al., 1980) . Target cells were either EMT6 (H-2 d) or L-929 (H-2 k) inoculated with 5 to 10 p.f.u./cell of one of the following viruses: HSV-1 (strain F), vgBll, vgD52 (a vaccinia virus recombinant that expresses HSV-1 gD) (Cremer et al., 1985) or vHA36 (a recombinant vaccinia virus which expresses influenza virus haemagglutinin antigen) (Smith et al., 1983) . Six h after virus inoculation, the target cells were labelled for 45 min at 37 °C with sodium [51Cr]chromate. Target cells were then washed three times and 104 cells in 100 ~tl were placed in 96-well round bottom microtitre plates. Effector cells (100 ~tl) were then added in various effector :target cell ratios. After a 4 h incubation at 37 °C, supernatants from each well were harvested using a Skatron collection system (Microbiological Associates, Walkersville, Md., U.S.A.) and 51Cr release was measured in a gamma counter.
The results in Fig. 1 show lysis of target cells by splenocytes from vgB11-immunized mice restimulated in vitro with either HSV-1 (a) or vgBll (b). Clearly, vgBll vaccination induced H-2-restricted anti-HSV CTL as demonstrated by the lysis of syngeneic, but not allogeneic, HSV-1-infected target cells. The vgB 11-immune splenocytes restimulated with vgB 11 (b) lysed HSV-1-, vgB 11-and vHA36-infected syngeneic target cells. The lysis was both specific and H-2-restricted, as neither uninfected EMT6 nor HSV-l-infected allogeneic target cells were lysed. Lysis of vHA36 target cells was expected since immunization with the recombinant vaccinia virus vector would induce anti-vaccinia virus CTL in addition to anti-gB CTL. Analogous studies on mice vaccinated with vgD52 showed CTL against all vaccinia virus-infected syngeneic targets but not against HSV-l-infected syngeneic targets (data not shown), confirming the results of others that gD is not a CTL target antigen (Blacklaws et al., 1987; Rosenthal et al., 1987; .
Splenocytes from vgB11-immunized mice that were restimulated in vitro with HSV-1 (Fig. 1 a) also showed specific, H-2-restricted lysis of target cells bearing HSV-1 antigens. Lysis of vHA36 targets by these splenocytes indicates that some anti-vaccinia virus CTL persist 11 days postvaccination with the splenocytes in culture for the last 5 of these days. It is possible that anti- vaccinia virus CTL were maintained because of the conditioned media generated by the secondary stimulation of HSV-l-specific CTL. Support for this explanation comes from an additional experiment in which mice were vaccinated with vHA36 and then restimulated in culture with either vHA36 or with HSV-1 (data not shown). No lysis of any of the targets occurred with HSV-1 restimulation. With vHA36 restimulation, there was lysis of EMT6 cells infected with vHA36 and vgB11, but there was no lysis of EMT6 cells infected with HSV-1 or uninfected EMT6 cells.
To confirm that HSV-1 gB is a CTL target antigen, unlabelled target cell inhibition of lysis was performed using the same immunization schedule (Fig. 2) . The radiolabelled targets were HSV-l-infected EMT6 cells throughout and the effector to radiolabelled target cell ratio was kept constant at 100 : 1. Additional unlabelled target cells expressing various viral proteins were added to the radiolabelled target cells at ratios of 50 : 1 to 6.25 : 1. The results show that inhibition of lysis of the radiolabelled HSV-l-infected targets occurred only by the addition of unlabelled syngeneic targets expressing HSV-1 antigens (HSV-1 and vgB11-infected cells). There was no competition by syngeneic targets expressing vaccinia viral antigens without HSV-1 gB (vHA36) and no competition by HSV-l-infected allogeneic unlabelled targets.
In summary, using a recombinant vaccinia virus we have shown that the HSV-1 glycoprotein B can both induce CTL and serve as a target antigen for CTL. These results are consistent with those of Blacklaws et al. (1987) but differ from those of Rosenthal et al. (1987) . Both studies were done in the H-2 k system with transformed cell lines as the immunogens. Differences in experimental procedures, particularly the lack of stimulation in vitro, may explain the failure of the latter study to demonstrate gB-specific CTL. Using a recombinant that expresses influenza virus haemagglutinin under the control of early and late vaccinia promoters, Coupar et al. (1987) were able to induce CTL in CBA/H mice only with the early promoter. Mouse strain differences Short communication are clearly important in that a CTL response was induced with either promoter in BALB/c mice, although in vitro restimulation of memory CTL in influenza virus-infected BALB/c and CBA/H mice was successful only with the early and not the late vaccinia promoter. The gB in vgBl 1 is under control of a late vaccinia virus promoter (Chakrabarti et al., 1985; Cantin et al., 1987) .
What remains to be determined is the effect of different vaccinia virus promoters on the induction of gB-specific CTL and the relative importance of gB as a CTL target during in vivo HSV-1 infection.
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